Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  American Journal of Physiology. Endocrinology and Metabolism

• Publication date

  2004-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1152/AJPENDO.00545.2003PMID 15271645
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes

  2006cited by this paper
• Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell.

  2004cited by this paper
• Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation

  2004cited by this paper
• Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes.

  2003cited by this paper
• International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels

  2003cited by this paper
• Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

  2003cited by this paper
• Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis*

  2003cited by this paper
• β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes

  2003cited by this paper
• The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects.

  2003cited by this paper
• Glucagon-like peptide-1 mobilizes intracellular Ca2+ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 beta-cells.

  2003cited by this paper
• GLP‐1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells

  2003cited by this paper
• Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.

  2003cited by this paper
• A novel pathway for regulation of glucose‐dependent insulinotropic polypeptide receptor expression in β‐cells

  2003cited by this paper
• Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes.

  2003cited by this paper
• Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects.

  2003cited by this paper
• The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.

  2003cited by this paper
• Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes.

  2003cited by this paper
• International Union of Pharmacology. XXXV. The Glucagon Receptor Family

  2003cited by this paper
• Oxyntomodulin suppresses appetite and reduces food intake in humans.

  2003cited by this paper
• Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects.

  2003cited by this paper
• GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine.

  2003cited by this paper
• Beta-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia.

  2002cited by this paper
• Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study.

  2002cited by this paper
• Therapy of type 2 diabetes mellitus based on the actions of glucagon‐like peptide‐1

  2002cited by this paper
• Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

  2002cited by this paper
• Glucose-dependent Insulinotropic Polypeptide Activates the Raf-Mek1/2-ERK1/2 Module via a Cyclic AMP/cAMP-dependent Protein Kinase/Rap1-mediated Pathway*

  2002cited by this paper
• Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide.

  2002cited by this paper
• Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients.

  2001cited by this paper
• Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats.

  2001cited by this paper
• Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes.

  2001cited by this paper
• A New Pathway for Glucose-dependent Insulinotropic Polypeptide (GIP) Receptor Signaling

  2001cited by this paper
• Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling.

  2001cited by this paper
• Breast Cancer Research and Treatment

  2001cited by this paper
• Printed in U.S.A. Copyright © 2000 by The Endocrine Society Glucose-Dependent Insulinotropic Polypeptide Confers Early Phase Insulin Release to Oral Glucose in Rats: Demonstration by a Receptor Antagonist*

  2000cited by this paper
• Life and death of the pancreatic beta cells.

  2000influential reference
• Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats.

  2000cited by this paper
• Life and Death of the Pancreatic β Cells

  2000cited by this paper
• Glucagon-Like Peptide-1 Induces Cell Proliferation and Pancreatic-Duodenum Homeobox-1 Expression and Increases Endocrine Cell Mass in the Pancreas of Old, Glucose-Intolerant Rats.

  2000cited by this paper
• The Glucagon Receptor Family

  2000cited by this paper
• Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.

  2000cited by this paper
• Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: evidence of several aberrations

  1999cited by this paper
• Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells.

  1999cited by this paper
• Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice.

  1999cited by this paper
• Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells

  1999cited by this paper
• Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39.

  1999cited by this paper
• Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats.

  1999cited by this paper
• Glucagon-Like Peptide 1(7-36) Amide Stimulates Exocytosis in Human Pancreatic β-Cells by Both Proximal and Distal Regulatory Steps in Stimulus-Secretion Coupling

  1998cited by this paper
• Mouse pancreatic beta-cells exhibit preserved glucose competence after disruption of the glucagon-like peptide-1 receptor gene.

  1998cited by this paper
• Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell responses and functional expression studies in Chinese hamster fibroblast cells

  1998cited by this paper
• Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1

  1998cited by this paper
• The pathogenesis of NIDDM involves a defective expression of the GIP receptor

  1997cited by this paper
• Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM

  1997cited by this paper
• Protein Kinase A-Dependent Stimulation of Exocytosis in Mouse Pancreatic β-Cells by Glucose-Dependent Insulinotropic Polypeptide

  1997cited by this paper
• Glucagon-Like Peptide I and Glucose-Dependent Insulinotropic Polypeptide Stimulate Ca2+-Induced Secretion in Rat α-Cells by a Protein Kinase A–Mediated Mechanism

  1997cited by this paper
• Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus.

  1997cited by this paper
• Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.

  1996cited by this paper
• Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene

  1996cited by this paper
• Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat.

  1996cited by this paper
• Identification of Two Missense Mutations in the GIP Receptor Gene: A Functional Study and Association Analysis with NIDDM: No Evidence of Association with Japanese NIDDM Subjects

  1996cited by this paper
• Glucagon-Like Peptide I Enhances the Insulinotropic Effect of Glibenclamide in NIDDM Patients and in the Perfused Rat Pancreas

  1996cited by this paper
• Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide.

  1995cited by this paper
• Reduction of the Incretin Effect in Rats by the Glucagon-Like Peptide 1 Receptor Antagonist Exendin (9–39) Amide

  1995cited by this paper
• Functional expression of the rat pancreatic islet glucose-dependent insulinotropic polypeptide receptor: ligand binding and intracellular signaling properties.

  1995cited by this paper
• Glucagon-like peptide I increases cytoplasmic calcium in insulin-secreting beta TC3-cells by enhancement of intracellular calcium mobilization.

  1995cited by this paper
• Glucagon-like peptide-1 is a physiological incretin in rat.

  1995cited by this paper
• The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects.

  1994cited by this paper
• Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.

  1993cited by this paper
• Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37)

  1993cited by this paper
• Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

  1993cited by this paper
• Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells.

  1992cited by this paper
• Entero-insular axis and diabetes mellitus.

  1992cited by this paper
• Neural mechanisms in the control of blood glucose concentration.

  1989cited by this paper
• Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8.

  1989cited by this paper
• Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs.

  1988cited by this paper
• Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach.

  1988cited by this paper
• Immunoreactive gastric inhibitory polypeptide.

  1988cited by this paper
• Glucagon-like peptide-1 7-36: a physiological incretin in man.

  1987cited by this paper
• Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor.

  1987cited by this paper
• Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas.

  1986cited by this paper
• Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.

  1986cited by this paper
• Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing.

  1986cited by this paper
• Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours

  1983cited by this paper
• Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours.

  1983cited by this paper
• Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption

  1983cited by this paper
• Influence of gastric inhibitory polypeptide antiserum on glucose-induced insulin secretion in rats.

  1982cited by this paper
• Depression of insulin release by anti-GIP serum after oral glucose in rats.

  1981cited by this paper
• Depression of insulin release with anti-GIP serum after oral glucose in rats

  1980cited by this paper
• Gastric inhibitory polypeptide (GIP) and insulin release after small-bowel resection in man.

  1980cited by this paper
• Effect of secretin on basal- and glucose-stimulated insulin secretion in man

  1978cited by this paper
• Stimulation of insulin secretion by gastric inhibitory polypeptide in man.

  1973cited by this paper
• Entero-insular axis.

  1969cited by this paper
• Stimulation of insulin secretion by glucagon and secretin.

  1968cited by this paper
• Intestinal factors in the control of insulin secretion.

  1965cited by this paper

• Linagliptin Attenuates the Adverse Effects of a High-Sugar Diet on Insulin Sensitivity, Hippocampal Oxidative Stress, and Cognitive Function in Rats.

  2026cites this paper
• The Role of Dietary Fibers in the Management of Type 2 Diabetes: A Synthesis of Current Evidence and Clinical Implications.

  2026cites this paper
• Mathematical diabetes disease progression modeling in the integrated glucose-insulin model among individuals with impaired glucose tolerance from the Finnish Diabetes Prevention Study

  2026cites this paper
• Axis-based propagation of nanoplastic toxicity: organ–organ crosstalk and systemic pathophysiological outcomes

  2025cites this paper
• Brain insulin resistance mediated cognitive impairment and neurodegeneration: Type-3 diabetes or Alzheimer’s Disease

  2025cites this paper
• A neural entero-pancreatic pathway that regulates insulin secretion and glucose tolerance

  2025cites this paper
• Semaglutide, a glucagon-like peptide-1 receptor agonist, inhibits oral squamous cell carcinoma growth through P38 MAPK signaling pathway

  2025cites this paper
• Dietary bioactive compounds for type 2 diabetes: A comprehensive review of molecular interactions and mechanistic insights

  2025cites this paper
• Discovery and Evaluation of DA-302168S as an Efficacious Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist.

  2025cites this paper
• Molecular dynamics insights into the binding interactions of semaglutide with human serum albumin.

  2025cites this paper
• Impact of GLP-1 receptor agonists on gastrointestinal function and symptoms

  2025cites this paper
• Effect of Almond Milk Versus Cow Milk on Postprandial Glycemia, Lipidemia, and Gastrointestinal Hormones in Patients with Overweight or Obesity and Type 2 Diabetes: A Randomized Controlled Clinical Trial

  2025cites this paper
• Intestinal fructose metabolism triggers a glucagon‐like peptide‐1–β‐cell axis to prevent post‐fructose hyperglycaemia

  2025influential citation
• Common channel length and implications to the weight loss

  2025cites this paper
• GLP-1 receptor agonism in cardiovascular disease prevention

  2025cites this paper
• The incretin effect in type 2 diabetes in a Sub-Saharan African population

  2024cites this paper
• Feline Diabetes Is Associated with Deficits in Markers of Insulin Signaling in Peripheral Tissues

  2024cites this paper
• Binding sites and design strategies for small molecule GLP-1R agonists.

  2024cites this paper
• Therapeutic benefits of incretin hormones beyond glycemic control from a primary care perspective: A Narrative Review

  2024cites this paper
• Second Generation Anti-Obesity Medications

  2024cites this paper
• Investigating incretins: a review of the use of GLP-1 and GIP receptor agonists for weight loss

  2024cites this paper
• Liraglutide improved the reproductive function of obese mice by upregulating the testicular AC3/cAMP/PKA pathway

  2024cites this paper
• The role of glucagon-like peptide-1/GLP-1R and autophagy in diabetic cardiovascular disease

  2024cites this paper
• Safety of native glucose-dependent insulinotropic polypeptide in humans.

  2024cites this paper
• GLP-1 and its derived peptides mediate pain relief through direct TRPV1 inhibition without affecting thermoregulation

  2024cites this paper
• Factors Correlated to the Renoprotective Effect of Sitagliptin in Patients with Type 2 Diabetes Mellitus: Retrospective Observational Study

  2024cites this paper
• Incretin-based therapy: a new horizon in diabetes management

  2024cites this paper
• Manipulation of Post-Prandial Hyperglycaemia in Type 2 Diabetes: An Update for Practitioners

  2024cites this paper
• Fasting GLP-1 Levels in Women with PCOS and CAH

  2024cites this paper
• Optimizing expression, purification, structural and functional assessments of a novel dimeric incretin (GLP-1cpGLP-1).

  2023cites this paper
• Unlocking Therapeutic Synergy: Tailoring Drugs for Comorbidities such as Depression and Diabetes through Identical Molecular Targets in Different Cell Types

  2023cites this paper
• G Protein-Coupled Receptors and the Rise of Type 2 Diabetes in Children

  2023cites this paper
• Changes in the Incretin Levels After Gastric Bypass

  2023cites this paper
• Rectal sensitivity correlated with gastrointestinal‐mediated glucose disposal, but not the incretin effect

  2023cites this paper
• Efficacy and safety of cetagliptin as monotherapy in patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled phase 3 trial

  2023cites this paper
• First-phase insulin secretion: can its evaluation direct therapeutic approaches?

  2023cites this paper
• Serum Obestatin Levels in PCOS and its Relation with Homa-IR

  2023cites this paper
• Discovery of Novel 5,6-Dihydro-1,2,4-triazine Derivatives as Efficacious Glucagon-Like Peptide-1 Receptor Agonists.

  2023cites this paper
• GIP und GLP-1-Rezeptoragonismus in der Therapie des Typ 2 Diabetes mit Fokus auf Tirzepatid

  2023cites this paper
• Tirzepatide: Clinical review of the "twincretin" injectable.

  2023cites this paper
• Both osmolality-dependent and independent mechanisms are associated with acute hyperglycemia-induced cardiovascular adverse reactions: Analysis of the mutual interactions leading to cardiovascular phenotypes in dogs.

  2023cites this paper
• Bile acids metabolism in the gut-liver axis mediates liver injury during lactation.

  2023cites this paper
• Standard procedures for blood withdrawal in conscious male rats induce stress and profoundly affect glucose tolerance and secretion of glucoregulatory hormones

  2023cites this paper
• Pathophysiology of Prediabetes, Diabetes, and Diabetic Remission in Cats.

  2023cites this paper
• Feeding during the resting phase causes gastrointestinal tract dysfunction and desynchronization of metabolic and neuronal rhythms in rats

  2023cites this paper
• Oral semaglutide - Rybelsus®, the first GLP-1 receptor agonist for oral use in clinical practice.

  2022cites this paper
• Glucagon-like Peptide-1 Receptor Agonists (GLP1-RA)

  2022cites this paper
• Diabetic Peripheral Neuropathy Associated with Cardiovascular Risk Factors and Glucagon-Like Peptide-1 Concentrations Among Newly Diagnosed Patients with Type 2 Diabetes Mellitus

  2022cites this paper
• A view at postbariatric hypoglycemia by endocrinologist

  2022cites this paper
• The Feeding Pattern of C57BL/6J Mice

  2022cites this paper
• The Role of incretin-based therapies in maintaining glucose homeostasis and management of diabetes mellitus

  2022cites this paper
• Effects of Vegetables Consumption Before Carbohydrates on Blood Glucose and GLP-1 Levels Among Diabetic Patients in Indonesia

  2022cites this paper
• Loureirin B promotes insulin secretion through GLP-1R and AKT/PDX1 pathways.

  2022cites this paper
• Effects of GLP-1 and GIP on Islet Function in Glucose Intolerant, Pancreatic Insufficient Cystic Fibrosis.

  2022cites this paper
• Effects of calcium salts of palm oil inclusion and ad libitum feeding regimen on growth performance, carcass characteristics, and plasma glucose-dependent insulinotropic polypeptide concentration of feedlot steers.

  2022cites this paper
• Dopamine Negatively Regulates Insulin Secretion Through Activation of D1-D2 Receptor Heteromer.

  2022cites this paper
• DMSO_A_344532 35..44

  2022cites this paper
• Biased Agonism and Polymorphic Variation at the GLP-1 Receptor: Implications for the Development of Personalised Therapeutics.

  2022cites this paper
• Production of active Exendin-4 in Nicotiana benthamiana and its application in treatment of type-2 diabetics

  2022cites this paper
• Effects of dietary fat and protein on glucoregulatory hormones in adolescents and young adults with type 1 diabetes.

  2021cites this paper
• The manifold roles of protein S-nitrosylation in the life of insulin

  2021cites this paper
• Tombul hazelnut (Corylus avellana L.) peptides with DPP-IV inhibitory activity: In vitro and in silico studies

  2021cites this paper
• Detour Ahead: Incretin Hormone Signaling Alters Its Intracellular Path as β-Cell Failure Progresses During Diabetes

  2021cites this paper
• Theaflavins prevent the onset of diabetes through ameliorating glucose tolerance mediated by promoted incretin secretion in spontaneous diabetic Torii rats

  2021cites this paper
• Impact of oral anticholinergic on insulin response to oral glucose load in patients with impaired glucose tolerance

  2021cites this paper
• Diabetic Kinome Inhibitors—A New Opportunity for β-Cells Restoration

  2021cites this paper
• Plasma glucagon-like peptide-1 responses to ingestion of protein with increasing doses of milk minerals rich in calcium

  2021cites this paper
• Effect of one-week administration of dipeptidyl peptidase-IV inhibitory peptides from chum salmon milt on postprandial blood glucose level: a randomised, placebo-controlled, double-blind, crossover, pilot clinical trial.

  2021cites this paper
• Riceberry rice (Oryza sativa L.) slows gastric emptying and improves the postprandial glycaemic response

  2021cites this paper
• Main Organs Involved in Glucose Metabolism

  2021cites this paper
• S1P Signaling Pathways in Pathogenesis of Type 2 Diabetes

  2021cites this paper
• Studies on the Use of Agricultural Food Products to Improve Intestinal Environment and Function

  2021cites this paper
• Poly ethylene glycol (PEG)-Related controllable and sustainable antidiabetic drug delivery systems.

  2021cites this paper
• Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective

  2021influential citation
• Hyperglycaemia in the Newborn Infant. Physiology Verses Pathology

  2021cites this paper
• In vitro and in silico DPP-IV inhibitory activities of 256 different hazelnut peptides

  2021cites this paper
• Establishment of a long-term stable β-cell line and its application to analyze the effect of Gcg expression on insulin secretion

  2021cites this paper
• Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence

  2020cites this paper
• Gs/Gq signaling switch in β cells defines incretin effectiveness in diabetes.

  2020cites this paper
• Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects

  2020cites this paper
• Role of Phosphodiesterase in the Biology and Pathology of Diabetes

  2020cites this paper
• Integrative transcriptomic analysis of pancreatic islets from patients with prediabetes/type 2 diabetes

  2020cites this paper
• Parameters interpretability in phenomenological-based semiphysical models. A human glucose homeostasis model

  2020cites this paper
• SYSTEMATIC REVIEW ON MEDICAMENTS USED IN MANAGEMENT OF DIABETES MELLITUS

  2020cites this paper
• DDDT_A_275343 5179..5187

  2020cites this paper
• Current State and Evidence of Cellular Encapsulation Strategies in Type 1 Diabetes.

  2020cites this paper
• Update on: effects of anti-diabetic drugs on bone metabolism

  2020cites this paper
• Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetes.

  2020cites this paper
• The Dose Effect of Whey Protein on Glycemic Control in Adults with Insulin Resistance

  2020cites this paper
• GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials

  2020cites this paper
• Recombinant Expression and Stapling of a Novel Long-Acting GLP-1R Peptide Agonist

  2020cites this paper
• A common human variant of GIPR improves systemic glucose homeostasis in a sexual dimorphic manner

  2020cites this paper
• Spatiotemporal regulation of GIPR signaling impacts glucose homeostasis as revealed in studies of a common GIPR variant

  2020cites this paper
• Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease.

  2020cites this paper
• Pathophysiology and Management of Disorders of Carbohydrate Metabolism and Neonatal Diabetes

  2020cites this paper
• Enteroendocrine Hormone Secretion and Metabolic Control: Importance of the Region of the Gut Stimulation

  2020cites this paper
• GPCR targets in type 2 diabetes

  2020cites this paper
• Role of dipeptidyl peptidase 4 in type 2 diabe tes mellitus

  2020cites this paper
• A brief review on newer Glucagon like Peptide-1 analogues

  2020cites this paper
• Incretin-based treatment of diabetes and cardiovascular complications.

  2020cites this paper